“医药健康+金融资本”双轮驱动 走中医药现代化发展之路
Zheng Quan Ri Bao·2026-01-05 22:49

Core Viewpoint - The Chinese traditional medicine industry is experiencing significant growth driven by policy support and increasing health demands, with a focus on balancing tradition and innovation [1] Group 1: Company Strategy - Jilin Aodong Pharmaceutical Group Co., Ltd. adopts a dual-driven strategy of "medicine health + financial capital" to modernize traditional Chinese medicine [1] - The company has established a robust capital collaborative network, holding 20.11% of Guangfa Securities and being a major shareholder in several pharmaceutical companies, which supports its main business [2][3] - Financial returns from investments in Guangfa Securities contributed 12.43 billion yuan and 17.49 billion yuan in 2023 and 2024 respectively, providing continuous financial support for the pharmaceutical business [3] Group 2: Financial Empowerment - The financial layout allows Jilin Aodong to maintain stable and abundant returns, which are reinvested into the pharmaceutical sector to alleviate the high risks and long cycles of research and development [3] - The company emphasizes a principle of "main business first, financial empowerment," ensuring that financial gains are directed back to support the core pharmaceutical operations [3] Group 3: Technological Innovation - Jilin Aodong places technological innovation at the core of its strategy, focusing on the research of key raw materials and advancing in fields like anti-aging and regenerative medicine [5] - The company has developed a closed-loop industrial chain around the breeding, processing, and quality control of deer antler, ensuring the quality and traceability of raw materials [5][6] - The implementation of modern technology in traditional practices is seen as essential for unlocking the core value of traditional Chinese medicine [5][6] Group 4: Industry Development - The modernization of traditional Chinese medicine is supported by national policies aimed at enhancing quality, digital transformation, and new drug development [4] - Jilin Aodong aims to reshape production factors through technological innovation, transitioning from resource-dependent to innovation-driven models [6] - The company is committed to continuous investment in research and development, enhancing its intelligent layout across the entire industrial chain, and maintaining its heritage as a time-honored brand [7]